High-dose therapy with autologous stem cell rescue for pediatric sarcomas Article Report uri icon

Overview

MeSH Major

  • Acetylmuramyl-Alanyl-Isoglutamine
  • Antineoplastic Agents
  • Bone Neoplasms
  • Liposomes
  • Lung Neoplasms
  • Osteosarcoma
  • Phosphatidylethanolamines

abstract

  • The published results do not demonstrate an unequivocal benefit for consolidation with high-dose therapy. Future trials of high-dose therapy must define rigorous eligibility criteria, must have an appropriate, preferably randomized, control group, and must be designed with sufficient power to evaluate the hypothesis.

publication date

  • March 2004

Research

keywords

  • Report

Identity

Digital Object Identifier (DOI)

  • 10.1097/00001622-200403000-00006

PubMed ID

  • 15075902

Additional Document Info

start page

  • 120

end page

  • 5

volume

  • 16

number

  • 2